Continuous Treatment to Address Residual Disease in Multiple Myeloma

William Bensinger MD of the Swedish Cancer Institute discusses an important topic for patients with multiple myeloma (MM): the impact of residual disease on the choice to treat patients continuously. Dr Bensinger explains why patients who achieve a complete response may still have up to 100 million residual myeloma cells, and how the absence of treatment post transplant may lead to a shorter remission.

Dr. Bensinger was compensated by Celgene for his participation in this video.